Gsk (GSK) Non-Current Assets (2009 - 2026)
Gsk (GSK) posted quarterly Non-Current Assets of $59.3 billion for Q2 2026, up 6.85% year-over-year from $55.5 billion in Q2 2025, and down 2.53% quarter-over-quarter from $60.8 billion in Q1 2026.
Gsk (GSK) Non-Current Assets (2009 - 2026) Analysis & Trends
Gsk's Non-Current Assets history runs 18 years deep, the most recent figure standing at $59.3 billion for Q2 2026.
- In Q2 2026, Non-Current Assets rose 6.85% year-over-year to $59.3 billion; the TTM figure through Jun 2026 stood at $59.3 billion (up 6.85% YoY), while the FY2025 annual figure was $57.5 billion, up 5.92% from the prior year.
- Non-Current Assets for Q2 2026 stood at $59.3 billion, down from $60.8 billion in the prior quarter.
- The five-year high for Non-Current Assets was $60.8 billion in Q1 2026, with the low at $39.9 billion in Q1 2022.
- The 5-year median for Non-Current Assets is $52.3 billion (2024), against an average of $51.8 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slumped 51.43% in 2022, then advanced 18.48% in 2023.
- Gsk's Non-Current Assets stood at $46.2 billion in 2022, then climbed by 8.46% to $50.1 billion in 2023, then gained by 8.81% to $54.5 billion in 2024, then gained by 6.42% to $58.0 billion in 2025, then climbed by 2.19% to $59.3 billion in 2026.
- Business Quant data shows GSK's Non-Current Assets at $59.3 billion in Q2 2026, $60.8 billion in Q1 2026, and $58.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.27 Bn |
| Mar 31, 2026 | 60.81 Bn |
| Dec 31, 2025 | 58.01 Bn |
| Sep 30, 2025 | 58.69 Bn |
| Jun 30, 2025 | 55.48 Bn |
| Mar 31, 2025 | 53.68 Bn |
| Dec 31, 2024 | 54.51 Bn |
| Sep 30, 2024 | 52.95 Bn |
| Jun 30, 2024 | 52.13 Bn |
| Mar 31, 2024 | 52.40 Bn |
| Dec 31, 2023 | 50.09 Bn |
| Sep 30, 2023 | 50.19 Bn |
| Jun 30, 2023 | 50.20 Bn |
| Mar 31, 2023 | 47.26 Bn |
| Dec 31, 2022 | 46.19 Bn |
| Sep 30, 2022 | 47.22 Bn |
| Jun 30, 2022 | 43.90 Bn |
| Mar 31, 2022 | 39.89 Bn |
| Dec 31, 2021 | 81.46 Bn |
| Sep 30, 2021 | 83.31 Bn |